These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis. Boulicault D; Duddy M Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449 [No Abstract] [Full Text] [Related]
26. Dimethyl fumarate-associated transient bone marrow oedema syndrome. Triplett J; Vijayan S; Prince R; Kermode A Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766 [TBL] [Abstract][Full Text] [Related]
27. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis. Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887 [TBL] [Abstract][Full Text] [Related]
28. What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials. Lanzillo R Eur J Neurol; 2017 May; 24(5):661-662. PubMed ID: 28332255 [No Abstract] [Full Text] [Related]
29. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J; Chamoux C; Hammès F; Chicoye A PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273 [TBL] [Abstract][Full Text] [Related]
32. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk. Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059 [TBL] [Abstract][Full Text] [Related]
33. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179 [TBL] [Abstract][Full Text] [Related]
34. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis. Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269 [TBL] [Abstract][Full Text] [Related]
36. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis]. Popova EV; Boyko AN; Orlova EV Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614 [TBL] [Abstract][Full Text] [Related]
37. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis]. Shmidt TE Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100 [TBL] [Abstract][Full Text] [Related]
38. Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera). Di Bona D; Albanesi M; Giliberti LA; Nico A; Rossi MP; Caiaffa MF; Macchia L J Allergy Clin Immunol Pract; 2017; 5(3):821-822. PubMed ID: 27888036 [No Abstract] [Full Text] [Related]
39. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631 [TBL] [Abstract][Full Text] [Related]
40. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Guarnera C; Bramanti P; Mazzon E Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]